Prostate Cancer Patient To Access Drugs After NHIF Deal

By Soko Directory Team / Published June 30, 2022 | 1:24 pm




KEY POINTS

NHIF covers six sessions for the first-line treatment for up to Ksh25,000 per session, four sessions for second-and third-line treatment for up to Ksh150,000 per session, and 20 sessions of radiotherapy at Ksh3,600 per session.


Prostate Cancer

KEY TAKEAWAYS


At the diagnosis level, the cover includes a biopsy under the surgical package in addition to Radiology including MRIs, ultrasounds, or CT and PET scans.


Prostate cancer patients covered by the National Hospital Insurance Fund (NHIF) can now access an innovator prescription drug manufactured and distributed by Janssen Kenya, one of the pharmaceutical companies of Johnson & Johnson, as part of strategic development to expand access to quality treatment regimes in Kenya.

Following the signing of a joint Memorandum of Understanding (MoU) between NHIF and Johnson & Johnson Middle East FZ-LLC (Janssen Kenya), the prescription drug, Abiraterone Acetate was used for the treatment of advanced prostate cancer will be made available to NHIF members within their existing benefits package.

Speaking after witnessing the MoU signing by NHIF and Janssen, Ministry of Health Principal Secretary Susan Mochache in a speech read on her behalf by NHIF Chairperson Lewis Nguyai described the partnership as a landmark development that will help boost the local access to innovator drugs.

The Ministry of Health and NHIF, she said, has been actively engaging innovative pharmaceutical companies to seal similar private-public partnership agreements that will facilitate access to innovator drugs at affordable rates.

“The Ministry of Health and NHIF has sealed this landmark MoU with Janssen as part of our ongoing foundation building to ensure the success of the Universal Health Coverage (UHC) national rollout. We are proud to be associated with Janssen for taking the lead in opening up access to an innovator drug such as Abiraterone Acetate, which will enhance positive health outcomes for prostate cancer patients,” Mochache said.

Visiting Senior Vice President for Emerging Markets at Janssen Pharmaceutical Companies of Johnson & Johnson Mr. Asgar Rangoonwala reiterated the company´s commitment to boosting access to innovative medicines in emerging economies. The company, he confirmed, is pursuing public-private partnerships to enhance access to safe, effective medicines and vaccines in developing countries for the most vulnerable patients.

Said Rangoonwala: “At Janssen, we are committed to advancing medical innovations that address unmet health needs in resource-limited settings. The MoU signed with NHIF is one of our partnerships to rollout new access models and equitable pricing strategies that improve the availability of our medicines to patients in emerging countries such as Kenya.”

NHIF CEO Dr. Peter Kamunyo echoed the importance of the partnership in Universal Health Coverage, confirming that NHIF has reviewed and expanded the range of benefits available for cancer patients. He said the review of benefits is geared toward alleviating the plight of cancer patients and increasing access to medication.

“The Fund’s core mandate is to provide medical insurance cover to all its members by ensuring that the range of benefits remains value-filled. The spirit of UHC is to ensure access to quality and consistent healthcare services needed by all Kenyans without having to be impoverished because of the high medical bills. We are negotiating for such innovations so that the cost of medication required to save lives fits within the packages offered,” Dr. Kamunyo said.

AMREF Health Africa Group CEO Dr. Githinji Gitahi speaking at the event lauded the partnership which he noted will help alleviate the plight of patients undergoing cancer treatment. While reiterating the need for a functional cancer registry to guide response strategies, Dr. Gitahi highlighted the need for patient-centered approaches to healthcare delivery.

Currently, the NHIF cancer care package entails up to 10 chemotherapy sessions, oral and injectable anti-cancer drugs, inpatient, and outpatient oncology services, 20 sessions for radiotherapy, and up to two sessions for Brachytherapy for advanced cancer, per year. The health facilities that offer the package include some level five and six hospitals and selected private hospitals in urban centers.

NHIF covers six sessions for the first-line treatment for up to Ksh25,000 per session, four sessions for second-and third-line treatment for up to Ksh150,000 per session, and 20 sessions of radiotherapy at Ksh3,600 per session. At the diagnosis level, the cover includes a biopsy under the surgical package in addition to Radiology including MRIs, ultrasounds, or CT and PET scans.

Cancer remains one of the major non-communicable diseases in Kenya and ranks third as a cause of death after infectious diseases and cardiovascular diseases. It is estimated that there are 42,000 new cases annually and approximately 28,000 cancer-related deaths every year. More than 70% of cancer cases are diagnosed late when treatment outcomes are poor, and palliative care is usually the only management amenable.

Related Content: Public Hospitals Need More Radiotherapy Machines to Prevent Cancer Deaths




About Soko Directory Team

Soko Directory is a Financial and Markets digital portal that tracks brands, listed firms on the NSE, SMEs and trend setters in the markets eco-system.Find us on Facebook: facebook.com/SokoDirectory and on Twitter: twitter.com/SokoDirectory

View other posts by Soko Directory Team


More Articles From This Author








Trending Stories










Other Related Articles










SOKO DIRECTORY & FINANCIAL GUIDE



ARCHIVES

2022
  • January 2022 (293)
  • February 2022 (329)
  • March 2022 (360)
  • April 2022 (294)
  • May 2022 (271)
  • June 2022 (232)
  • July 2022 (278)
  • August 2022 (67)
  • 2021
  • January 2021 (182)
  • February 2021 (227)
  • March 2021 (325)
  • April 2021 (259)
  • May 2021 (285)
  • June 2021 (273)
  • July 2021 (277)
  • August 2021 (232)
  • September 2021 (271)
  • October 2021 (305)
  • November 2021 (364)
  • December 2021 (249)
  • 2020
  • January 2020 (272)
  • February 2020 (310)
  • March 2020 (390)
  • April 2020 (321)
  • May 2020 (335)
  • June 2020 (327)
  • July 2020 (333)
  • August 2020 (276)
  • September 2020 (214)
  • October 2020 (233)
  • November 2020 (242)
  • December 2020 (187)
  • 2019
  • January 2019 (251)
  • February 2019 (215)
  • March 2019 (283)
  • April 2019 (254)
  • May 2019 (269)
  • June 2019 (249)
  • July 2019 (335)
  • August 2019 (293)
  • September 2019 (306)
  • October 2019 (313)
  • November 2019 (362)
  • December 2019 (318)
  • 2018
  • January 2018 (291)
  • February 2018 (213)
  • March 2018 (275)
  • April 2018 (223)
  • May 2018 (235)
  • June 2018 (176)
  • July 2018 (256)
  • August 2018 (247)
  • September 2018 (255)
  • October 2018 (282)
  • November 2018 (282)
  • December 2018 (184)
  • 2017
  • January 2017 (183)
  • February 2017 (194)
  • March 2017 (207)
  • April 2017 (104)
  • May 2017 (169)
  • June 2017 (205)
  • July 2017 (189)
  • August 2017 (195)
  • September 2017 (186)
  • October 2017 (235)
  • November 2017 (253)
  • December 2017 (266)
  • 2016
  • January 2016 (164)
  • February 2016 (165)
  • March 2016 (189)
  • April 2016 (143)
  • May 2016 (245)
  • June 2016 (182)
  • July 2016 (271)
  • August 2016 (247)
  • September 2016 (233)
  • October 2016 (191)
  • November 2016 (243)
  • December 2016 (153)
  • 2015
  • January 2015 (1)
  • February 2015 (4)
  • March 2015 (164)
  • April 2015 (107)
  • May 2015 (116)
  • June 2015 (119)
  • July 2015 (145)
  • August 2015 (157)
  • September 2015 (186)
  • October 2015 (169)
  • November 2015 (173)
  • December 2015 (205)
  • 2014
  • March 2014 (2)
  • 2013
  • March 2013 (10)
  • June 2013 (1)
  • 2012
  • March 2012 (7)
  • April 2012 (15)
  • May 2012 (1)
  • July 2012 (1)
  • August 2012 (4)
  • October 2012 (2)
  • November 2012 (2)
  • December 2012 (1)
  • 2011
    2010
    2009
    2008
    2007
    2006
    2005
    2004
    2003
    2002
    2001
    2000
    1999
    1998
    1997
    1996
    1995
    1994
    1993
    1992
    1991
    1990
    1989
    1988
    1987
    1986
    1985
    1984
    1983
    1982
    1981
    1980
    1979
    1978
    1977
    1976
    1975
    1974
    1973
    1972
    1971
    1970
    1969
    1968
    1967
    1966
    1965
    1964
    1963
    1962
    1961
    1960
    1959
    1958
    1957
    1956
    1955
    1954
    1953
    1952
    1951
    1950